Treatment of Multicentric Castleman's disease accompanying multiple myeloma with bortezomib: A case report

23Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology and characterized by various clinical manifestations and multiple organ involvement. It has been reported in association with POEMS syndrome and can progress to Kaposi's sarcoma or malignant lymphoma. The disease runs a more aggressive course and a poor prognosis. Optimal therapies have not been well established up to now. We here reported a case of rare M CD complicated with multiple myeloma who received bortezomib and achieved very good remission. To our knowledge, this is the first report on MCD in the setting of multiple myeloma with good response to bortezomib. © 2009 Yuan et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Yuan, Z. G., Dun, X. Y., Li, Y. H., & Hou, J. (2009). Treatment of Multicentric Castleman’s disease accompanying multiple myeloma with bortezomib: A case report. Journal of Hematology and Oncology, 2. https://doi.org/10.1186/1756-8722-2-19

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free